Overview

Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of different doses of asimadoline in the treatment of patients with irritable bowel syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Tioga Pharmaceuticals
Collaborator:
RTI Health Solutions